Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
LASTOCKS19
LASTOCKS19 Jul. 16 at 8:07 AM
$ABUS Arbutus Biopharma is being included (again) in the Solactive U.S. Biotechnology Index, effective Aug 7, 2025. What that means. More passive fund buying Increased visibility in biotech Potential short-term price boost and longterm
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Jul. 15 at 3:58 PM
$ABUS Does anyone know or have an educated guess when the next AB-101 clinical data might be revealed? End of year?
3 · Reply
StockosaurusTex
StockosaurusTex Jul. 15 at 11:35 AM
$ABUS
0 · Reply
SKCSS
SKCSS Jul. 14 at 10:06 PM
$ABUS It's as quiet in here as I've ever seen it.
2 · Reply
Grtgooglymoogly
Grtgooglymoogly Jul. 14 at 8:01 PM
$ABUS Is that a pulse?
1 · Reply
Stocks_pumpr
Stocks_pumpr Jul. 14 at 8:00 PM
$ABUS
0 · Reply
Hjm57
Hjm57 Jul. 11 at 11:26 PM
$ABUS Any answers on why Judge Goldberg has been replaced?
2 · Reply
BLOODLUST91
BLOODLUST91 Jul. 11 at 7:50 PM
$ABUS Trump was a fan of this judge, and he even voted for him and not only that we know how Trump and Republicans feel about all the Covid and vaccine stuff anyway... I have a feeling I know how this might go. Now that Goldberg isn’t protecting Moderna and in doing so being forced to protect Pfizer, I think that this really begins to speed up finally.
3 · Reply
Nile1
Nile1 Jul. 11 at 7:22 PM
$ABUS if nobody is selling why it dropped ? I tried to add on the bid side today but never filled my order
1 · Reply
NakdEnergy
NakdEnergy Jul. 11 at 6:12 PM
$ABUS this is a great board with excellent DD and relevant input that’s objectively positive based on the facts. That being said, who the hell is selling this to keep the price down?
1 · Reply
Latest News on ABUS
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 20 days ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 2 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 2 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 3 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 3 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 3 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 4 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 5 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Jan 30, 2025, 3:40 PM EST - 5 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 6 months ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jan 7, 2025, 7:56 AM EST - 6 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 8 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 8 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 8 months ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 8 months ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:52 PM EST - 8 months ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 9 months ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 9 months ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 11 months ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 1 year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 1 year ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:06 AM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 1 year ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 1 year ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 18, 2023, 7:30 AM EDT - 1 year ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Oct 11, 2023, 8:05 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Jul 20, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Jul 12, 2023, 7:30 AM EDT - 2 years ago

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Arbutus Appoints Two New Executives

Jul 10, 2023, 4:01 PM EDT - 2 years ago

Arbutus Appoints Two New Executives

LASTOCKS19
LASTOCKS19 Jul. 16 at 8:07 AM
$ABUS Arbutus Biopharma is being included (again) in the Solactive U.S. Biotechnology Index, effective Aug 7, 2025. What that means. More passive fund buying Increased visibility in biotech Potential short-term price boost and longterm
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Jul. 15 at 3:58 PM
$ABUS Does anyone know or have an educated guess when the next AB-101 clinical data might be revealed? End of year?
3 · Reply
StockosaurusTex
StockosaurusTex Jul. 15 at 11:35 AM
$ABUS
0 · Reply
SKCSS
SKCSS Jul. 14 at 10:06 PM
$ABUS It's as quiet in here as I've ever seen it.
2 · Reply
Grtgooglymoogly
Grtgooglymoogly Jul. 14 at 8:01 PM
$ABUS Is that a pulse?
1 · Reply
Stocks_pumpr
Stocks_pumpr Jul. 14 at 8:00 PM
$ABUS
0 · Reply
Hjm57
Hjm57 Jul. 11 at 11:26 PM
$ABUS Any answers on why Judge Goldberg has been replaced?
2 · Reply
BLOODLUST91
BLOODLUST91 Jul. 11 at 7:50 PM
$ABUS Trump was a fan of this judge, and he even voted for him and not only that we know how Trump and Republicans feel about all the Covid and vaccine stuff anyway... I have a feeling I know how this might go. Now that Goldberg isn’t protecting Moderna and in doing so being forced to protect Pfizer, I think that this really begins to speed up finally.
3 · Reply
Nile1
Nile1 Jul. 11 at 7:22 PM
$ABUS if nobody is selling why it dropped ? I tried to add on the bid side today but never filled my order
1 · Reply
NakdEnergy
NakdEnergy Jul. 11 at 6:12 PM
$ABUS this is a great board with excellent DD and relevant input that’s objectively positive based on the facts. That being said, who the hell is selling this to keep the price down?
1 · Reply
RL123
RL123 Jul. 11 at 5:34 PM
$ABUS just do an $INKT and I’ll be happy
1 · Reply
TruthTooPower
TruthTooPower Jul. 11 at 4:19 PM
$ABUS !!! What is PT When They Resolve The Court Case? $25.00
2 · Reply
GABIRODZ01
GABIRODZ01 Jul. 11 at 3:55 PM
$ABUS Goodbye Judge Goldberg?
2 · Reply
Thepatientone
Thepatientone Jul. 11 at 3:05 PM
$ABUS - 3
0 · Reply
Thepatientone
Thepatientone Jul. 11 at 3:05 PM
$ABUS - 2
0 · Reply
Thepatientone
Thepatientone Jul. 11 at 3:04 PM
$ABUS -
0 · Reply
Thepatientone
Thepatientone Jul. 11 at 2:57 PM
$ABUS -
1 · Reply
Thalassophile
Thalassophile Jul. 11 at 2:56 PM
$ABUS tempted to buy more, bur have abus enuui.
1 · Reply
Thecheese12
Thecheese12 Jul. 11 at 2:29 PM
$ABUS apparently the market doesnt like the new judge
1 · Reply
Heavey
Heavey Jul. 11 at 5:06 AM
$ABUS IMO a conflict of interest
3 · Reply
BLOODLUST91
BLOODLUST91 Jul. 10 at 8:36 PM
$ABUS any updates? I haven’t seen anything. Why the hell isn’t Pfizer marksman out yet
1 · Reply
NoBSPls
NoBSPls Jul. 10 at 4:57 PM
$ABUS It looks like MRNA is on winning streak with their European patent suits against PFE/BNTX. Any impact on us??
1 · Reply